3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
28
Lung Neoplasms
13
Gliosarcoma
13
Carcinoma, Non-Small-Cell Lung
13
Rectal Neoplasms
12
Brain Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Sarcoma
9
Prostatic Neoplasms
9
Breast Neoplasms
9
Astrocytoma
9
Uterine Cervical Neoplasms
8
Melanoma
8
Glioma
8
Esophageal Neoplasms
8
Pancreatic Neoplasms
7
Head and Neck Neoplasms
7
Neoplasm Metastasis
5
Lymphoma, Follicular
5
Oropharyngeal Neoplasms
4
Lymphoma, Mantle-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Squamous Cell
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Multiple Myeloma
3
Mouth Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, B-Cell
3
Interventions
Cyclophosphamide
12
fludarabine
10
fludarabine phosphate
7
Radiotherapy
6
Mycophenolic Acid
6
Whole-Body Irradiation
5
Sirolimus
5
Filgrastim
5
Tacrolimus
4
Melphalan
4
Busulfan
4
Peripheral Blood Stem Cell Transplantation
3
Methylprednisolone
3
Cyclosporine
3
Thiotepa
2
Stem Cell Transplantation
2
Specimen Handling
2
Rituximab
2
Methotrexate
2
Mesna
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
venetoclax
1
siplizumab
1
rasburicase
1
prostaglandin D2 receptor
1
milatuzumab
1
itacitinib
1
eritoran
1
Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Graft vs Host Disease
×
Radiation
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled